Does Roche Still Offer Value After a 35.9% Rally and New Oncology Partnerships? [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
the price, this article will walk through what the numbers are really indicating about the stock. Roche shares have climbed 2.7% over the last week, 4.9% in the past month, and 26.9% year to date, with a 35.9% gain over the last 12 months that has investors rethinking both upside potential and downside risk. Recent headlines have focused on Roche expanding its pipeline through strategic partnerships in oncology and immunology, while also increasing its focus on diagnostics and personalized medicine to support long term growth. These moves, along with continued investment in innovation and targeted acquisitions, help explain why the market has been willing to re-rate the shares. Even after that rally, Roche scores a 4/6 valuation check, suggesting the market may not be fully recognizing its fundamentals yet. Next, we will break down what different valuation approaches indicate about that gap and introduce a more nuanced way to think about value by the end of this article. Roche
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- FDA approves Roche's Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma [Yahoo! Finance]Yahoo! Finance
- FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular LymphomaBusiness Wire
- Roche CEO points to higher future drug prices in Switzerland after US deal [Yahoo! Finance]Yahoo! Finance
- Roche CEO points to higher future drug prices in Switzerland after US deal [Yahoo! Finance Canada]Yahoo! Finance Canada
- Nine Drugmakers Strike Deals With Trump, With More to Come [Yahoo! Finance Canada]Yahoo! Finance Canada